… Advantages of biweekly versus weekly administration of cetuximab for patients with
metastatic colorectal cancer (mCRC), and squamous cell carcinoma of the head and neck (SCCHN) …

… Cetuximab is classified as a biologic agent and has a radiosensitizing effect (18–20). It is
approved for the treatment of squamous cell carcinoma of the head and neck … plus cetuximab. …

… Recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is
currently an incurable disease. To improve treatment strategies, combinations of cetuximab plus …

… inhibitor palbociclib in combination with the EGFR inhibitor cetuximab and the PD-L1 inhibitor
avelumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). …

… of albumin into cells to serve as a nutrient supply and is constitutively driven by signaling
pathways frequently hyperactivated in head and neck squamous-cell carcinoma (HNSCC). In …

… safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the
EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma (R/M …

… Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell
… of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in …

… has been from the results of clinical trials in head and neck cancer. A phase III clinical trial
… advanced squamous cell carcinoma of the head and neck, the addition of cetuximab nearly …

… (R/M) head and neck squamous cell carcinoma (HNSCC). The … carboplatin, paclitaxel and
cetuximab was associated with … vs weekly chemotherapy plus cetuximab after progression on …

… patients with bulky unresectable tumors with cetuximab and concurrent radiotherapy …
tumors involving head and neck primary sites. It should be noted, that while synergy of cetuximab …